{"id":"NCT03212521","sponsor":"AbbVie","briefTitle":"Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1","officialTitle":"A Single Arm, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment Naïve Adults With Chronic Hepatitis C Virus (HCV) Genotypes 1 - 6 Infection and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤ 1","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-08-07","primaryCompletion":"2018-08-13","completion":"2018-08-13","firstPosted":"2017-07-11","resultsPosted":"2019-09-04","lastUpdate":"2019-09-04"},"enrollment":230,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C Virus (HCV)"],"interventions":[{"type":"DRUG","name":"Glecaprevir/Pibrentasvir","otherNames":["ABT-493/ABT-530","MAVYRET™"]}],"arms":[{"label":"Glecaprevir/Pibrentasvir","type":"EXPERIMENTAL"}],"summary":"A study to evaluate the efficacy and safety of glecaprevir(GLE)/pibrentasvir(PIB) in treatment-naïve participants with chronic hepatitis C virus (HCV) genotypes 1-6 infection and with an aspartate aminotransferase to platelet ratio index (APRI) of less than or equal to 1.","primaryOutcome":{"measure":"Percentage of Participants in the Modified Intention-to-Treat Population With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)","timeFrame":"12 weeks after the last actual dose of study drug, Week 20","effectByArm":[{"arm":"Glecaprevir/Pibrentasvir","deltaMin":100,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":null},"locations":{"siteCount":42,"countries":["United States","Bulgaria","Canada","France","Germany","Poland","Puerto Rico","Russia","Spain","United Kingdom"]},"refs":{"pmids":["31646465"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":230},"commonTop":["HEADACHE","FATIGUE"]}}